Date: 2016-08-22
Type of information: Establishment of a new subsidiary in the EU
Compound: DS102, DS107
Company: DS Biopharma (Ireland) Afimmune (Ireland)
Therapeutic area: Dermatologic diseases - Fibrotic diseases - Liver diseases - Hepatic diseases - Lung diseases - Rare diseases - Respiratory diseases
Type agreement: establishment of a new subsidiary in the EU
Action mechanism:
Disease: atopic dermatitis, pruritus, NASH (non-alcoholic steatohepatitis), chronic obstructive pulmonary disease (COPD), Idiopathic pulmonary fibrosis (IPF)
Details: * On August 22, 2016, DS Biopharma, a privately held drug discovery and development company with industry-leading expertise in lipid science, announced the launch of a spin-out company focused solely on fibrotic conditions such as non-alcoholic steatohepatitis (NASH) and pulmonary disorders such as chronic obstructive pulmonary disease (COPD) and Idiopathic pulmonary fibrosis (IPF). DS Biopharma will focus on the development of DS107 (oral formulation of dihomo gamma linolenic acid - DGLA)., an anti-inflammatory compound for atopic dermatitis and pruritus and DS109 for other inflammatory skin disorders such as acne. Both Topical and Oral DS107 are planned to begin separate phase IIb clinical studies later this year. DS Biopharma also expects to bring DS109, which is being explored as a treatment for inflammatory skin disorders, into the clinic later this year.
The new company, Afimmune, will continue the clinical development of DS102, a novel, anti-fibrotic compound. Afimmune plans to start a phase IIa study with DS102 in NASH patients later this year, this compound having been shown to be safe and well tolerated in a phase I trial. The company also plans to start a phase IIa clinical trial in COPD patients following positive pre-clinical data. Afimmune has also a number of other compounds in pre-clinical development.
Financial terms:
Latest news:
